Public Citizen petitions FDA to ban DTC drug ads
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Public Citizen petitioned the FDA to ban direct-to-consumer (DTC) advertising of prescription medicines, arguing the ads "mislead consumers because they are designed to persuade rather than to inform or educate patients"
- Public Citizen said DTC ads employ "emotional manipulation techniques or visual distractions to highlight information about benefits" while minimizing risks
- The Trump administration announced a "crackdown" on deceptive drug advertising last September, disclosing plans for new rules and stronger enforcement
- The FDA followed the crackdown by sending dozens of letters to drugmakers flagging problems with their prescription drug ads
- The Trump administration has been leaning on drugmakers to provide more balanced information in their prescription drug ads, creating a policy backdrop for the petition
Why it matters: The Trump administration is already pushing drugmakers for more balanced ad content following last September's enforcement crackdown, which generated dozens of warning letters. Public Citizen's petition goes much further — demanding a full DTC ad ban — putting the FDA on a collision course between its incremental enforcement track and a wholesale prohibition pushed by outside advocates.
